PolyPid to Participate in The Citizens Life Sciences Conference
Rhea-AI Summary
PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has announced its participation in The Citizens Life Sciences Conference in New York. The company's management will engage in a fireside chat on Wednesday, May 7, 2025, at 10:30 AM ET.
During the two-day conference, scheduled for May 7-8, 2025, the PolyPid management team will also be available for one-on-one investor meetings. Interested investors can arrange meetings through their Citizens JMP representatives.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, PYPD declined 1.45%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
PETACH TIKVA, Israel, April 22, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s management will participate in a fireside chat at The Citizens Life Sciences Conference taking place in New York, NY, from May 7-8, 2025.
| Citizens Life Sciences Conference Fireside Chat | |
| Date: | Wednesday, May 7, 2025 |
| Time: | 10:30 AM ET |
The PolyPid management team will participate in one-on-one investor meetings during this event. Investors interested in meeting with PolyPid around the conference should contact their Citizens JMP representative.
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.
For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.
Contacts:
PolyPid Ltd.
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com
Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
britchie@lifesciadvisors.com